MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Harpoon Therapeutics Cash and Cash Equivalents 2011-2026 | HARP
Annual Cash and Cash Equivalents Harpoon Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.6 M | 44.7 M | 21.2 M | 88.7 M | 89.5 M | 29.4 M | 985 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 89.5 M | 985 K | 46.6 M |
Quarterly Cash and Cash Equivalents Harpoon Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.7 M | 32.8 M | 61.4 M | 51.6 M | 51 M | 69.2 M | 50.7 M | 44.7 M | 43 M | 77.4 M | 71.3 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 88.7 M | 88.7 M | 88.7 M | 88.7 M | 89.5 M | 89.5 M | 89.5 M | 89.5 M | 29.4 M | - | - | - | 985 K | - | - | - | 2.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 89.5 M | 985 K | 53.9 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
129 M | $ 3.52 | -1.26 % | $ 1.05 B |  Canada |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
36.3 M | $ 3.22 | 2.88 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.8 | 1.81 % | $ 4.36 M | China |
 |
ADC Therapeutics SA
ADCT
|
326 M | $ 4.13 | -1.67 % | $ 105 M | Schweiz |
 |
argenx SE
ARGX
|
1.5 B | $ 709.52 | 0.88 % | $ 25 B |  Niderland |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.4 | -5.82 % | $ 8.18 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
616 M | $ 228.5 | -1.09 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
95.7 M | $ 6.1 | 0.83 % | $ 497 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
231 M | $ 6.6 | -0.45 % | $ 181 M |  Israel |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
37.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
72.9 M | $ 14.52 | 1.11 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
BioCardia
BCDA
|
1.1 M | $ 1.3 | 2.36 % | $ 27.5 M | USA |
 |
Aptose Biosciences
APTO
|
6.15 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
70.5 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.67 | 1.14 % | $ 16.8 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.49 | -1.32 % | $ 380 M | Britain |
 |
Athira Pharma
ATHA
|
48.4 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 92.62 | 2.3 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 8.28 | 2.73 % | $ 1.35 B | Britain |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |
 |
Actinium Pharmaceuticals
ATNM
|
72.9 M | $ 1.16 | 4.5 % | $ 34.9 M | USA |